Potential therapeutic implications of next generation sequencing (NGS)-based molecular profiling in HR+/HER2-metastatic breast cancer (mBC)

被引：0
|
作者：
Avesani, Barbara
Giontella, Elena
Caldart, Alberto
De Noni, Alessandro
Muzzarelli, Alice
Borghesani, Giulia
Insolda, Jessica
Biondani, Pamela
Parolin, Veronica
Pellini, Francesca
Scarpa, Aldo
Nottegar, Alessia
Lawlor, Rita T.
Mafficini, Andrea
Paris, Ida
Minucci, Angelo
Pasciuto, Tina
Fabi, Alessandra
Fiorio, Elena
Milella, Michele
机构：
[1] Azienda Osped Univ Integrata Verona, Med Oncol, Verona, Italy
[2] Azienda Osped Univ Integrata Verona, Verona, Italy
[3] Azienda Osped Univ Integrata Verona, Sect Breast Surg, Verona, Italy
[4] Univ Verona, Sect Pathol, Dept Diagnost & Publ Hlth, Verona, Italy
[5] Hosp Trust Verona, Verona, Italy
[6] Univ Verona, Sect Pathol, Verona, Italy
[7] ARC NET, Verona, Italy
[8] Fdn Policlin Univ Agostino Gemelli IRCCS, Rome, Italy
[9] Univ Cattolica Sacro Cuore, Dept Unit Mol & Genom Diagnost, Fdn Policlin Univ Agostino Gemelli IRCCS, Rome, Italy
[10] Univ Cattolica Sacro Cuore, Policlin Agostino Gemelli, Rome, Italy
[11] IRCCS, Precis Med Senol, Fdn Policlin Univ Agostino Gemelli, Rome, Italy
[12] Univ Verona Hosp Trust, Dept Oncol, Verona, Italy
[13] Univ Verona, Sch Med, Sect Oncol, Verona, Italy
[14] Verona Univ Hosp Trust, Verona, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13079
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Sequencing Therapies: Optimal Treatment for HR+/HER2- Metastatic Breast Cancer
    Kaklamani, Virginia
    Rugo, Hope S.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2024, 22 (01) : 25 - 27
  • [22] Real-world palbociclib dosing patterns and implications for drug costs in the treatment of HR+/HER2-metastatic breast cancer
    Li, Nanxin
    Du, Ella X.
    Chu, Lihao
    Peeples, Miranda
    Xie, Jipan
    Barghout, Victoria
    Tang, Derek H.
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (12) : 1167 - 1178
  • [23] Identifying Drivers of First-Line HR+/HER2-Metastatic Breast Cancer Treatment Choices
    Brufsky, Adam M.
    Maculaitis, Martine C.
    Kopenhafer, Lewis
    Olsen, Patrick
    Cha, Ashley S.
    Arruda, Lillian Shahied
    Heck, Wendy
    Kurosky, Samantha K.
    CANCER RESEARCH, 2023, 83 (05)
  • [24] Patient and treatment characteristics in HR+/HER2-metastatic breast cancer in a real-life setting
    Karadurmus, Nuri
    Sendur, Mehmet Ali Nahit
    Cil, Timucin
    Oksuzoglu, Omur Berna Cakmak
    Arslan, Cagatay
    Harputluoglu, Hakan
    Goksu, Sema Sezgin
    Ozturk, Banu
    MevludeInanc
    Cubukcu, Erdem
    Demirci, Umut
    Erdem, Dilek
    Cihan, Sener
    Tural, Deniz
    Dumludag, Aysegul
    Yilmaz, Funda
    Avsar, Esin
    Sonusen, Sermin Dinc
    Ozturk, Ozge Fulya
    Aver, Birkan
    Kaplan, Muhammet Ali
    CANCER RESEARCH, 2023, 83 (05)
  • [25] The association between age, toxicity and outcomes of abemaciclib treatment in HR+/HER2-metastatic breast cancer
    Ovcaricek, Tanja
    Matos, Erika
    Borstnar, Simona
    Ribnikar, Domen
    Kuhar, Cvetka Grasic
    Cankar, Kaja
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [26] Genomic Profiling of Premenopausal HR+ and HER2-Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib
    Bardia, Aditya
    Su, Fei
    Solovieff, Nadia
    Im, Seock-Ah
    Sohn, Joohyuk
    Lee, Keun Seok
    Campos-Gomez, Saul
    Jung, Kyung Hae
    Colleoni, Marco
    Villanueva Vazquez, Rafael
    Franke, Fabio
    Hurvitz, Sara
    Harbeck, Nadia
    Chow, Louis
    Taran, Tetiana
    Lorenc, Karen Rodriguez
    Babbar, Naveen
    Tripathy, Debu
    Lu, Yen-Shen
    JCO PRECISION ONCOLOGY, 2021, 5 : 1408 - 1420
  • [27] Treatment patterns and characteristics of postmenopausal women with HR+/HER2-metastatic breast cancer receiving everolimus
    Vekeman, Francis
    Hao, Yanni
    Cheng, Wendy Y.
    Fortier, Jonathan
    Robitaille, Marie-Noelle
    Duh, Mei Sheng
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 114 - 115
  • [28] Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2-Metastatic Breast Cancer
    Dalal, Anand A.
    Gagnon-Sanschagrin, Patrick
    Burne, Rebecca
    Guerin, Annie
    Gauthier, Genevieve
    Small, Tania
    Niravath, Polly
    ADVANCES IN THERAPY, 2018, 35 (06) : 768 - 778
  • [29] A multicenter analysis of abemaciclib after progression on palbociclib in patients (pts) with hormone receptor-positive (HR+)/HER2-metastatic breast cancer (MBC).
    Wander, Seth Andrew
    Zangardi, Mark
    Niemierko, Andrzej
    Kambadakone, Avinash
    Kim, Leslie S. L.
    Xi, Jing
    Pandey, Apurva Kumari
    Spring, Laura
    Stein, Casey
    Juric, Dejan
    Kuter, Irene
    Moy, Beverly
    Mulvey, Therese Marie
    Vidula, Neelima
    Isakoff, Steven J.
    Yuen, Megan
    Brufsky, Adam
    Ma, Cynthia X.
    O'Shaughnessy, Joyce
    Bardia, Aditya
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [30] Concordance of circulating tumor DNA (ctDNA) and next-generation sequencing (NGS) as molecular monitoring tools in metastatic breast cancer (MBC)
    Austin, Laura K.
    Avery, Tiffany
    Jaslow, Rebecca
    Fortina, Paolo
    Sebisanovic, Dragan
    Siew, LaiMun
    Zapanta, Aubrey
    Talasaz, AmirAli
    Cristofanilli, Massimo
    CANCER RESEARCH, 2015, 75
12345